- Home
- PHAT vs CBAN Comparison
PHAT vs CBAN Comparison
Compare PHAT & CBAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- CBAN
- Stock Information
- Founded
- PHAT 2018
- CBAN 1975
- Country
- PHAT United States
- CBAN United States
- Employees
- PHAT N/A
- CBAN N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- CBAN Major Banks
- Sector
- PHAT Health Care
- CBAN Finance
- Exchange
- PHAT Nasdaq
- CBAN Nasdaq
- Market Cap
- PHAT 289.0M
- CBAN 285.4M
- IPO Year
- PHAT 2019
- CBAN 1998
- Fundamental
- Price
- PHAT $4.25
- CBAN $15.29
- Analyst Decision
- PHAT Strong Buy
- CBAN
- Analyst Count
- PHAT 4
- CBAN 0
- Target Price
- PHAT $16.25
- CBAN N/A
- AVG Volume (30 Days)
- PHAT 2.2M
- CBAN 56.2K
- Earning Date
- PHAT 05-01-2025
- CBAN 07-23-2025
- Dividend Yield
- PHAT N/A
- CBAN 3.01%
- EPS Growth
- PHAT N/A
- CBAN 14.66
- EPS
- PHAT N/A
- CBAN 1.43
- Revenue
- PHAT $81,859,000.00
- CBAN $113,756,000.00
- Revenue This Year
- PHAT $195.45
- CBAN $18.25
- Revenue Next Year
- PHAT $106.76
- CBAN $7.59
- P/E Ratio
- PHAT N/A
- CBAN $10.67
- Revenue Growth
- PHAT 3055.70
- CBAN 3.33
- 52 Week Low
- PHAT $2.21
- CBAN $11.26
- 52 Week High
- PHAT $19.71
- CBAN $18.49
- Technical
- Relative Strength Index (RSI)
- PHAT 54.83
- CBAN 45.90
- Support Level
- PHAT $3.92
- CBAN $14.63
- Resistance Level
- PHAT $4.35
- CBAN $15.80
- Average True Range (ATR)
- PHAT 0.40
- CBAN 0.40
- MACD
- PHAT 0.13
- CBAN -0.09
- Stochastic Oscillator
- PHAT 85.63
- CBAN 36.67
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About CBAN Colony Bankcorp Inc.
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.